Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Sudden Cardiac Arrest – Doc Fischer talks about CARL. in SWR-TV

It can happen to anyone at any time. Around 65,000 people in Germany suffer from cardiac arrest every year. The time and duration of resuscitation efforts are crucial factors that directly impact the chances of neurologically intact survival. 

The SWR-health programme ‘Doc Fischer’ explains the causes of sudden cardiac arrest and how the new CARL-Therapy can improve survival rates, both in- and out-of-hospital.

Image: SWR

Prof. Georg Trummer from the Medical Center – University of Freiburg, and Prof. Christoph Benk, Chief Technology Officer at Resuscitec, explain the advanced extracorporeal circulation therapy developed specifically for resuscitation use.

20 years of research and development result into a unique ad hoc patient-monitoring of relevant vital parameters to perform a patient-individualized, controlled and automated reperfusion of the whole body. For patients, this means an improved chance of neurologically intact survival after refractory cardiac arrest.

Video (minute 12:50)